Get the Stockscreener App
0.8283
6.21%
0.0484
Prelude Therapeutics Inc stock is traded at $0.8283, with a volume of 74,562.
It is up +6.21% in the last 24 hours and up +3.54% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.7799
Open:
$0.77
24h Volume:
74,562
Relative Volume:
0.47
Market Cap:
$46.77M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.4653
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-10.94%
1M Performance:
+3.54%
6M Performance:
-24.70%
1Y Performance:
-85.34%
1-Day Range:
$0.77
$0.8658
1-Week Range:
$0.77
$1.00
52-Week Range:
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.8283 | 44.03M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Should I hold or sell Prelude Therapeutics Incorporated stock in 2025Expert Picks Forecasts Backed By Experts - jammulinksnews.com
How to build a dashboard for Prelude Therapeutics Incorporated stockFree Quick Gain Stock Watch With Indicators - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyPrice Forecast Based on AI Analysis - Newser
Risk vs reward if holding onto Prelude Therapeutics IncorporatedMomentum Trend Signal Weekly Recap Summary - Newser
How does Prelude Therapeutics Incorporated compare to its industry peersBeginner Investor Data Feed For Every Investor - jammulinksnews.com
What are Prelude Therapeutics Incorporated company’s key revenue driversFinancial News Review For Consistent Profits - jammulinksnews.com
What catalysts could drive Prelude Therapeutics Incorporated stock higher in 2025Market Forecast Opportunities For Beginners - jammulinksnews.com
Why is Prelude Therapeutics Incorporated stock attracting strong analyst attentionAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
What institutional investors are buying Prelude Therapeutics Incorporated stockAI Powered Target Finder For Consistent Profits - jammulinksnews.com
Does Prelude Therapeutics Incorporated qualify in momentum factor screeningPrice Action Summary and Entry Strategy Guide - Newser
Best data tools to analyze Prelude Therapeutics Incorporated stockFree Low Risk Buy Zone Opportunity Watch - Newser
Using data models to predict Prelude Therapeutics Incorporated stock movementRisk Managed Watchlist with Breakout Picks - Newser
Can machine learning forecast Prelude Therapeutics Incorporated recoveryPredictable Entry Strategy With Technical Backing - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryTrade Flow Monitor with Volume Tracker - Newser
Has Prelude Therapeutics Incorporated found a price floorWeekly Trend Watch with Market Signals - Newser
Is Prelude Therapeutics Incorporated stock entering bullish territoryShort-Term Swing Opportunity Summary Sheet - Newser
Prelude Therapeutics Incorporated stock trendline breakdownFree Fundamental Growth Stock Analysis - Newser
Is Prelude Therapeutics Incorporated in Accumulation Phase NowCommunity Strategy With High Win Rate Backtested - metal.it
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionFree Real Market Momentum Signal Generator - Newser
Published on: 2025-07-29 06:27:17 - metal.it
Buy Signal for Prelude Therapeutics Incorporated Stock Key Technical Indicators to WatchMarket Forecast Summary Over Multi-Year Period - Newser
SRx Health Solutions Inc. recovery potential after sell offPrice Action Summary and Entry Strategy Guide - Newser
What is the dividend policy of Prelude Therapeutics Incorporated stockBuild your wealth with consistent stock growth - jammulinksnews.com
When is Prelude Therapeutics Incorporated stock expected to show significant growthExpert guidance for superior capital growth - jammulinksnews.com
What are the technical indicators suggesting about Prelude Therapeutics IncorporatedAchieve breakthrough results with expert guidance - jammulinksnews.com
Is it the right time to buy Prelude Therapeutics Incorporated stockDiscover stocks with strong growth potential - jammulinksnews.com
Prelude Therapeutics Incorporated Stock Performance After Earnings: Historical InsightsWeekly Big Movers - Newser
Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher – Time to Buy? - Defense World
What drives Prelude Therapeutics Incorporated stock priceUnmatched profit growth - PrintWeekIndia
Is Prelude Therapeutics Incorporated a good long term investmentSkyrocketing investment returns - PrintWeekIndia
What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional
Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):